Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.44 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2766913 | 0.89 | MGLL (0.48) | MGLLFAAHPTGDR2RORCCCR1 | |
| SCHEMBL2768728 | 0.87 | PTGDR2 (0.44) | MGLLFAAHPTGDR2RORCKCNH2 | |
| SCHEMBL2765722 | 0.87 | PTGDR2 (0.48) | MGLLFAAHPTGDR2RORCCCR1 | |
| SCHEMBL377619 | 0.85 | MGLL (0.43) | MGLLFAAHPTGDR2 | |
| SCHEMBL377620 | 0.84 | MGLL (0.38) | MGLLFAAHPTGDR2 | |
| SCHEMBL2766969 | 0.83 | MGLL (0.51) | MGLLFAAHPTGDR2RORC | |
| SCHEMBL2766842 | 0.82 | MGLL (0.48) | MGLLPTGDR2CCR1 | |
| SCHEMBL2785715 | 0.82 | MGLL (0.48) | MGLLPTGDR2CCR1 | |
| SCHEMBL20818264 | 0.80 | MGLL (0.52) | MGLLFAAHPTGDR2 | |
| SCHEMBL2766253 | 0.80 | MGLL (0.43) | MGLLFAAHPTGDR2RORCKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103108866-B | cyclohexane derivative compound | DAIICHI SANKYO Co.,Ltd. (JP) | 2015-09-09 | — | — | CN | disclosed |
| US-9051255-B2 | Piperazinyl cyclohexane compounds as GPR38 agonists | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-09 | — | — | US | disclosed |
| US-8853218-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| US-20140221392-A1 | CYCLOHEXANE DERIVATIVE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140221391-A1 | CYCLOHEXANE DERIVATIVE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-08-07 | — | — | US | disclosed |
| EP-2623492-B1 | CYCLOHEXANE DERIVATIVE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2014-05-14 | — | — | EP | disclosed |
| US-8710060-B2 | Piperazinyl methyl phenyl cyclohexane compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-04-29 | — | — | US | disclosed |
| US-20130289048-A1 | CYCLOHEXANE DERIVATIVE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-10-31 | — | — | US | disclosed |
| EP-2623492-A1 | CYCLOHEXANE DERIVATIVE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-08-07 | — | — | EP | disclosed |
| CN-103108866-A | Cyclohexane derivative compound | DAIICHI SANKYO CO LTD | 2013-05-15 | — | — | CN | disclosed |
| US-8236953-B2 | Process for preparing piper azine derivatives | GLAXO GROUP LIMITED (GB) | 2012-08-07 | — | — | US | disclosed |
| US-20100256364-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LTD. | 2010-10-07 | — | — | US | disclosed |
| EP-2212299-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | Glaxo Group Limited (GB) | 2010-08-04 | — | — | EP | disclosed |
| EP-2041093-B1 | PIPERAZINYL DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LTD (GB) | 2010-04-21 | — | — | EP | disclosed |
| US-7700599-B2 | G protein coupled receptor inhibitors (Gpr38) such as 6-[(4-fluorophenyl)oxy]-N-methyl-N-(4-{[(3S)-3-methyl-1-piperazinyl]methyl}phenyl)-3-pyridinecarboxamide for treatment of gastric stasis in an enterally fed patient | GLAXO GROUP LIMITED (GB) | 2010-04-20 | — | — | US | disclosed |
| US-20090192160-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2009-07-30 | — | — | US | disclosed |
| WO-2009068552-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2009-06-04 | — | — | WO | disclosed |
| US-20090131453-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20080027065-A1 | G protein coupled receptor inhibitors (Gpr38) such as 6-[(4-fluorophenyl)oxy]-N-methyl-N-(4-{[(3S)-3-methyl-1-piperazinyl]methyl}phenyl)-3-pyridinecarboxamide for treatment of gastric stasis in an enterally fed patient | GLAXO GROUP LIMITED (GB) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221392-A1 | CYCLOHEXANE DERIVATIVE COMPOUND | HRH2, CBR1, HRH4 | MGLL 2931/4885FAAH 993/4885PTGDR2 267/4885 |
| US-20100256364-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GPR68, GPR88, GIPR | MGLL 1048/4885FAAH 1098/4885PTGDR2 206/4885 |
| US-20090131453-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GPR68, GPR52, GPR88 | MGLL 1468/4885FAAH 1304/4885PTGDR2 220/4885 |
| US-20140221391-A1 | CYCLOHEXANE DERIVATIVE COMPOUND | HRH2, CBR1, HRH4 | MGLL 2931/4885FAAH 993/4885PTGDR2 267/4885 |
| US-20080027065-A1 | G protein coupled receptor inhibitors (Gpr38) such as 6-[(4-fluorophenyl)oxy]-N-methyl-N-(4-{[(3S)-3-methyl-1-piperazinyl]methyl}phenyl)-3-pyridinecarboxamide for treatment of gastric stasis in an enterally fed patient | GPR68, GPR88, GPR3 | MGLL 1411/4885FAAH 390/4885PTGDR2 83/4885 |
| US-20090192160-A1 | COMPOUNDS | GPR68, GPR88, GPBAR1 | MGLL 1402/4885FAAH 896/4885PTGDR2 132/4885 |
| US-20130289048-A1 | CYCLOHEXANE DERIVATIVE COMPOUND | HRH2, CBR1, HRH4 | MGLL 2931/4885FAAH 993/4885PTGDR2 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.